Toll-like receptors (TLRs) recognize microbial/viral-derived elements that trigger innate immune response and conflicting data implicate TLR agonists in cancer, either as protumor or antitumor brokers. HIF-1 expression in different prostate tumor cell lines underlie their differential response to TLR3 account…